Arkolith/Insider Trading/JSPR/Form 4

Mahal Jeetinder Singh

Chief Operating OfficerJasper Therapeutics, Inc. (JSPR) · full profile →Form 4 · filed Dec 12, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$20K
Net Open-Market Flow
-$20K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 12, 2024Option exercise(M)900$7.10$6K26K
Dec 12, 2024Sell(S)900$22.11$20K25K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 12, 2024Option exercise(M)900—$014K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-24-108551) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML